



Cite this: *Chem. Commun.*, 2015, 51, 4089

Received 15th January 2015,  
Accepted 3rd February 2015

DOI: 10.1039/c5cc00407a

www.rsc.org/chemcomm


# Oxidative Heck desymmetrisation of 2,2-disubstituted cyclopentene-1,3-diones†

S. E. Walker, C. J. C. Lamb, N. A. Beattie, P. Nikodemiak and A.-L. Lee\*

**Oxidative Heck couplings have been successfully developed for 2,2-disubstituted cyclopentene-1,3-diones. The direct coupling onto the 2,2-disubstituted cyclopentene-1,3-dione core provides a novel expedient way of enantioselectively desymmetrising all-carbon quaternary centres.**

The 2,2-disubstituted cyclopentene-1,3-dione core is found in several biologically active natural products, including madindolines A and B,<sup>1</sup> similin A<sup>2</sup> and ochroleucin A<sub>1</sub>,<sup>3</sup> and metabolites such as preussidone<sup>4</sup> and involutone<sup>5</sup> (e.g. Fig. 1). As such, a direct, catalytic method for accessing such motifs would be of synthetic value, but no examples of such methods were available at the commencement of this project.<sup>6,7</sup> We therefore aimed to develop a Heck-type<sup>8</sup> desymmetrisation on easily accessible substrates **1**<sup>9</sup> using chiral enantiopure ligands<sup>10</sup> (Scheme 1),<sup>11</sup> as this is in principle one of the most direct ways of obtaining the stereogenic all-carbon quaternary centre found in **2**.<sup>12</sup>

During the preparation of this manuscript, an elegant base-mediated organocatalytic alkylation method was reported by




**Scheme 1** Heck-type desymmetrisation of 2,2-disubstituted cyclopentene-1,3-diones.

Mukherjee and co-workers using nitroalkyls as the alkylating agent.<sup>13</sup> However, this alternative approach is necessarily limited to alkylations ( $R^3$  = alkyl in **2**), which precludes it as a method towards non-alkyl substituted target products such as involutone, ochroleucin A<sub>1</sub> and preussidone (Fig. 1). Therefore, the development of a Heck-type desymmetrisation, capable of *aryllating* enediones **1**, is still highly relevant for the access of other 2,2-disubstituted cyclopentene-1,3-dione targets.

Despite their obvious potential, Heck-type reactions have not previously been reported on cyclopentene-1,3-dione substrates such as **1**. This lack of literature precedence is most likely due to the fact that cyclic enones are notoriously reluctant to undergo Pd(0)-catalysed Mizoroki–Heck couplings and will often produce the conjugate addition products instead, as well as being stereochemically precluded from undergoing the final step in the traditional Pd(0) Heck cycle: the *syn*  $\beta$ -H elimination.<sup>14</sup> As substrates **1** are expected to be challenging substrates for the Heck-type reaction, our initial aim was to develop a racemic Heck-type protocol for **1**, followed by enantioselective desymmetrisations. Our successful efforts toward this goal are presented herein.

We decided to utilise Pd(II)-catalysed oxidative Heck<sup>10d,15,16</sup> methods as they have recently been shown to be more compatible with cyclic enones than Pd(0)-catalysed Heck couplings.<sup>17</sup> Nevertheless, examples of successful oxidative Heck couplings on cyclic enone derivatives are still fairly scarce<sup>18</sup> and do not include any examples of enediones. Therefore, a brief screen of conditions was carried out to evaluate the feasibility of such a reaction (Table 1). Firstly, our recently developed ligand- and base-free conditions for cyclohexenone derivatives<sup>18a,j,k</sup> failed



**Fig. 1** Examples of natural products containing 2,2-disubstituted cyclopentene-1,3-dione cores.


Institute of Chemical Sciences, School of Engineering and Physical Sciences,  
Heriot-Watt University, Edinburgh, EH14 4AS, UK. E-mail: A.Lee@hw.ac.uk;  
Tel: +44 (0)131-4518030

† Electronic supplementary information (ESI) available: Experimental procedures,  
<sup>1</sup>H NMR and <sup>13</sup>C NMR spectra and full characterisation of new compounds. See  
DOI: 10.1039/c5cc00407a





Table 3 Substrate scope: arylboroxines




<sup>a</sup> Commercial arylboronic acid (2 equiv.) is heated under vacuum to generate the arylboroxine prior to use. <sup>b</sup> Isolated yields. <sup>c</sup> Conditions as in Table 2. <sup>d</sup> Pd(OAc)<sub>2</sub> (4 × 5 mol%), phenanthroline (4 × 6 mol%).


addition of the catalyst and ligand was found to be ideal for better conversions (see ESI†). Using these conditions, the arylboroxine substrate scope study shows that a wide variety of arylboroxines are suitable coupling partners (Table 3). Electron-withdrawing (**2ca–2ea**) as well as electron-donating substituents (**2aa, 2fa–2ja**) are all tolerated well under the general reactions conditions as are *ortho* (**2fa**), *meta* (**2da, 2ga**) and *para* substituents (**2aa, 2ca, 2ea, 2ga–2ja**). Once again, tolerance to unprotected functional groups such as ketone (**2ea**), phenol (**2ha**), alcohol (**2ia**) and amide (**2ja**) is demonstrated. Furthermore, the ester, chloro and unprotected hydroxyl groups in **2ca, 2da** and **2ha–2ia** respectively also provide a handle for further functionalisation. Polycyclic aromatic groups (**2ka, 2la**), including 2-fluorene with a readily oxidisable position (**2la**) are also pleasingly tolerated.

Finally, initial attempts at enantioselective desymmetrisation using commercially available chiral PyOX ligands **6a**<sup>25</sup> or **6b**<sup>26</sup> produced very promising results (Table 4). In order to avoid issues with competitive ligation from DMF solvent,<sup>10d</sup> DMA was used as the solvent instead<sup>27</sup> and a lower temperature of 50 °C was also employed. To our delight, aryl substituted **1d–g** and naphthyl substituted **1h** substrates are desymmetrised in 74:26 to 94:6 er and excellent yields (85–100%) under these initial conditions, using both electron-donating (**3a, 3h**) and -withdrawing (**3m**) substituted aryl boroxines, thereby showing the promise and validity of our proposed idea in Scheme 1. A current limitation is that the er is modest when R is not an aryl substituent (e.g. Bn in **1a**, giving 65:35 er **2aa**).

In order to ascertain the absolute stereochemistry of **2** by comparison with a known structure, a one-step synthesis of preussidone<sup>4</sup> was attempted from **10**. To our delight, (+)-preussidone was successfully obtained in 79% yield and 85:15 er, without the need for OH protection (Scheme 2).<sup>28</sup> By comparison with literature values,<sup>4</sup> the *S* stereochemistry can be assigned for **20n** and thereby by analogy, also for the products in Table 4.

Table 4 Enantioselective oxidative Heck desymmetrisations of **1**

<sup>a</sup> Isolated yields. Er determined by chiral HPLC (Daicel IA or IB). <sup>b</sup> Using **6a**. <sup>c</sup> Using **6b**.



Scheme 2 Synthesis of (+)-preussidone.

In conclusion, oxidative Heck couplings have been developed for 2,2-disubstituted cyclopentene-1,3-diones **1** for the first time. These substrates were found to be more challenging oxidative Heck coupling partners compared to simple alkenes or cyclohexenones, as evidenced by the higher reaction temperatures (50–70 °C vs. RT) and stricter requirements for the dehydrated arylboroxine (vs. arylboronic acid). Nevertheless, the reaction is very functional group tolerant and reacts well even in the presence of unprotected alcohols, phenols, acids, amides and ketones. Our initial enantioselective results show that direct oxidative Heck reactions on 2,2-disubstituted cyclopentene-1,3-diones is potentially a powerful method to desymmetrise all-carbon quaternary centres on the cyclopentenone core (up to 94:6 er and quant. yields), as exemplified by the synthesis of (+)-preussidone. Further investigations into this enantioselective method are currently underway and will be reported in due course.

We thank James Jordan-Hore for preliminary experiments, EPSRC (SEW), and Erasmus (PN) for funding, the EPSRC UK National Mass Spectrometry Facility at Swansea University for analytical services and Johnson Matthey for loan of Pd(OAc)<sub>2</sub>.

## Notes and references

- (a) T. Hirose, T. Sunazuka, T. Shirahata, D. Yamamoto, Y. Harigaya, I. Kuwajima and S. Omura, *Org. Lett.*, 2002, **4**, 501; (b) T. Hirose, T. Sunazuka, D. Yamamoto, E. Kaji and S. Omura, *Tetrahedron Lett.*, 2006, **47**, 6761; (c) S. Hosokawa, K. Sekiguchi, K. Hayase, Y. Hirukawa and S. Kobayashi, *Tetrahedron Lett.*, 2000, **41**, 6435; (d) C. C. McComas, J. B. Perales and D. L. Van Vranken, *Org. Lett.*, 2002, **4**, 2337; (e) T. Sunazuka, T. Hirose, T. Shirahata, Y. Harigaya,



- M. Hayashi, K. Komiyama, S. Omura and A. B. Smith III, *J. Am. Chem. Soc.*, 2000, **122**, 2122; (f) L. Wan and M. A. Tius, *Org. Lett.*, 2007, **9**, 647.
- 2 H. A. Weber, D. C. Swenson, J. B. Gloer and D. Malloch, *Tetrahedron Lett.*, 1992, **33**, 1157.
  - 3 B. Sontag, M. R  th, P. Spiteller, N. Arnold, W. Steglich, M. Reichert and G. Bringmann, *Eur. J. Org. Chem.*, 2006, 1023.
  - 4 L. Du, J. B. King, B. H. Morrow, J. K. Shen, A. N. Miller and R. H. Cichewicz, *J. Nat. Prod.*, 2012, **75**, 1819.
  - 5 (a) R. Antkowiak, W. Z. Antkowiak, I. Banczyk and L. Mikolajczyk, *Can. J. Chem.*, 2003, **81**, 118; (b) L. Mikolajczyk and W. Z. Antkowiak, *Heterocycles*, 2009, **79**, 423; (c) Z.-Y. Zhou and J.-K. Liu, *Nat. Prod. Rep.*, 2010, **27**, 1531.
  - 6 For a related report on Cu(I)-catalysed desymmetrisation *via* a two-step conjugate addition/oxidation method, see: (a) K. Aikawa, T. Okamoto and K. Mikami, *J. Am. Chem. Soc.*, 2012, **134**, 10329; for direct vinylogous nucleophilic addition of deconjugated butenolides using organocatalysts, see: (b) M. S. Manna and S. Mukherjee, *Chem. Sci.*, 2014, **5**, 1627.
  - 7 For review on desymmetrising cyclopentanes, see: M. S. Manna and S. Mukherjee, *Org. Biomol. Chem.*, 2015, **13**, 18.
  - 8 For recent reviews on asymmetric Heck and related reactions, see: (a) D. McCartney and P. J. Guiry, *Chem. Soc. Rev.*, 2011, **40**, 5122; (b) M. Oestreich, *Angew. Chem., Int. Ed.*, 2014, **53**, 2282; (c) H. Li, C. H. Ding, B. Xu and X. L. Hou, *Acta Chim. Sin.*, 2014, **72**, 765.
  - 9 See ESI† for details on substrate synthesis.
  - 10 For selected examples of intermolecular enantioselective oxidative Heck reactions, see: (a) T.-S. Mei, H. H. Patel and M. S. Sigman, *Nature*, 2014, **508**, 340; (b) T.-S. Mei, E. W. Werner, A. J. Burckle and M. S. Sigman, *J. Am. Chem. Soc.*, 2013, **135**, 6830; (c) S. Sakaguchi, K. S. Yoo, J. O'Neill, J. H. Lee, T. Stewart and K. W. Jung, *Angew. Chem., Int. Ed.*, 2008, **47**, 9326; (d) K. S. Yoo, C. P. Park, C. H. Yoon, S. Sakaguchi, J. O'Neill and K. W. Jung, *Org. Lett.*, 2007, **9**, 3933.
  - 11 For reviews of catalytic enantioselective desymmetrisations, see: (a) K. Mikami and A. Yoshida, *J. Synth. Org. Chem., Jpn.*, 2002, **60**, 732; (b) T. Rovis, in *New Frontiers in Asymmetric Catalysis*, ed. K. Mikami and M. Lautens, Wiley, Hoboken, NJ, 2007, p. 275; (c) R. S. Ward, *Chem. Soc. Rev.*, 1990, **19**, 1; (d) M. C. Willis, *J. Chem. Soc., Perkin Trans. 1*, 1999, 1765.
  - 12 *Quaternary Stereocenters: Challenges and Solutions for Organic Synthesis*, ed. J. Christoffers and A. Baro, Blackwell Science Publ, Oxford, 2005.
  - 13 M. S. Manna and S. Mukherjee, *J. Am. Chem. Soc.*, 2015, **137**, 130.
  - 14 (a) D. Tanaka and A. G. Myers, *Org. Lett.*, 2004, **6**, 433; (b) Y. Fall, H. Doucet and M. Santelli, *Tetrahedron*, 2009, **65**, 489.
  - 15 For reviews on oxidative Heck, see: (a) B. Karimi, H. Behzadnia, D. Elhamifar, P. F. Akhavan, F. K. Esfahani and A. Zamani, *Synthesis*, 2010, 1399; (b) Y. J. Su and N. Jiao, *Curr. Org. Chem.*, 2011, **15**, 3362.
  - 16 Selected papers on oxidative Heck, for examples on cyclic enones see ref. 17 and 18: (a) M. M. S. Andappan, P. Nilsson and M. Larhed, *Chem. Commun.*, 2004, 218; (b) C. S. Cho and S. Uemura, *J. Organomet. Chem.*, 1994, **465**, 85; (c) J. D. Crowley, K. D. Hanni, A.-L. Lee and D. A. Leigh, *J. Am. Chem. Soc.*, 2007, **129**, 12092; (d) J. H. Delcamp, A. P. Brucks and M. C. White, *J. Am. Chem. Soc.*, 2008, **130**, 11270; (e) J. H. Delcamp, P. E. Gormisky and M. C. White, *J. Am. Chem. Soc.*, 2013, **135**, 8460; (f) X. Du, M. Suguro, K. Hirabayashi, A. Mori, T. Nishikata, N. Hagiwara, K. Kawata, T. Okeda, H. F. Wang, K. Fugami and M. Kosugi, *Org. Lett.*, 2001, **3**, 3313; (g) Z. He, S. Kirchberg, R. Froehlich and A. Studer, *Angew. Chem., Int. Ed.*, 2012, **51**, 3699; (h) A. Inoue, H. Shinokubo and K. Oshima, *J. Am. Chem. Soc.*, 2003, **125**, 1484; (i) Y. C. Jung, R. K. Mishra, C. H. Yoon and K. W. Jung, *Org. Lett.*, 2003, **5**, 2231; (j) L. Meng, C. Liu, W. Zhang, C. Zhou and A. Lei, *Chem. Commun.*, 2014, **50**, 1110; (k) J. Ruan, X. Li, O. Saidi and J. Xiao, *J. Am. Chem. Soc.*, 2008, **130**, 2424; (l) Y. Su and N. Jiao, *Org. Lett.*, 2009, **11**, 2980; (m) P. Sun, Y. Zhu, H. Yang, H. Yan, L. Lu, X. Zhang and J. Mao, *Org. Biomol. Chem.*, 2012, **10**, 4512; (n) E. W. Werner and M. S. Sigman, *J. Am. Chem. Soc.*, 2010, **132**, 13981; (o) C. Zheng, D. Wang and S. S. Stahl, *J. Am. Chem. Soc.*, 2012, **134**, 16496.
  - 17 K. S. Yoo, C. H. Yoon and K. W. Jung, *J. Am. Chem. Soc.*, 2006, **128**, 16384.
  - 18 For example, see: (a) S. E. Walker, J. A. Jordan-Hore, D. G. Johnson, S. A. Macgregor and A.-L. Lee, *Angew. Chem., Int. Ed.*, 2014, **53**, 13876; (b) Y. W. Kim and G. I. Georg, *Org. Lett.*, 2014, **16**, 1574; (c) A. Carr  r, J.-D. Brion, S. Messaoudi and M. Alami, *Org. Lett.*, 2013, **15**, 5606; (d) A. L. Gottumukkala, J. F. Teichert, D. Heijnen, N. Eisink, S. van Dijk, C. Ferrer, A. van den Hoogenband and A. J. Minnaard, *J. Org. Chem.*, 2011, **76**, 3498; (e) Y. Izawa, C. Zheng and S. S. Stahl, *Angew. Chem., Int. Ed.*, 2013, **52**, 3672; (f) Y. Li, Z. Qi, H. Wang, X. Fu and C. Duan, *J. Org. Chem.*, 2012, **77**, 2053; (g) B. Mondal, S. Hazra and B. Roy, *Tetrahedron Lett.*, 2014, **55**, 1077; (h) D.-C. Xiong, L.-H. Zhang and X.-S. Ye, *Org. Lett.*, 2009, **11**, 1709; (i) K. S. Yoo, J. O'Neill, S. Sakaguchi, R. Giles, J. H. Lee and K. W. Jung, *J. Org. Chem.*, 2010, **75**, 95; (j) J. A. Jordan-Hore, J. N. Sanderson and A.-L. Lee, *Org. Lett.*, 2012, **14**, 2508; (k) S. E. Walker, J. Boehnke, P. E. Glen, S. Levey, L. Patrick, J. A. Jordan-Hore and A.-L. Lee, *Org. Lett.*, 2013, **15**, 1886. See also ref. 16a and 17.
  - 19 K. M. Gligorich and M. S. Sigman, *Chem. Commun.*, 2009, 3854.
  - 20 One possible explanation for this is that tautomerisation of the desired oxidative Heck product can now occur, allowing 1,2-addition (see ref. 21)/tautomerisation/coupling *via*  $\pi$ -allyl intermediate (see ref. 22) to produce the triarylated product **5an**.
  - 21 T. Yamamoto, T. Ohta and Y. Ito, *Org. Lett.*, 2005, **7**, 4153.
  - 22 Y. Kayaki, T. Koda and T. Ikariya, *Eur. J. Org. Chem.*, 2004, 4989.
  - 23 It should be noted that commercial aryl boronic acid samples are often a mixture of the aryl boronic acid and arylboroxine in equilibrium. D. G. Hall, *Boronic Acids*, Wiley-VCH Verlag GmbH & Co. KGaA, 2011, pp. 1–133.
  - 24 Alternatively, arylboronic acid pinacol esters can also be used, although the yields are slightly lower than with arylboronic acids. For example, **2bh** is formed in 84% and 78% yields using phenylboronic acid and pinacol ester respectively, under general conditions shown in Table 2.
  - 25 H. Shimizu, J. C. Holder and B. M. Stoltz, *Beilstein J. Org. Chem.*, 2013, **9**, 1637.
  - 26 E. W. Werner, T.-S. Mei, A. J. Burckle and M. S. Sigman, *Science*, 2012, **338**, 1455.
  - 27 R. Diaz-Torres and S. Alvarez, *Dalton Trans.*, 2011, **40**, 10742.
  - 28 The arylboronic acid pinacol ester **7n** was used here as it is commercially available while the corresponding arylboronic acid is not.

